Trial Profile

The European Cubicin(R) Outcomes Registry and Experience (EU-CORE[SM]), a non-interventional, multicenter, observational registry in patients receiving at least one dose of daptomycin between January 2006 and April 2012.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 18 May 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daptomycin (Primary)
Indications Bacteraemia; Gram-positive infections; Skin and soft tissue infections
Focus Therapeutic Use
Acronyms EU-CORE
Sponsors Novartis Pharma

12 Apr 2016 Results of pooled analysis of CORE and EU-CORE registries (n=11557) presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases
03 Feb 2016 Results from subgroup analysis of children and adolescent patients (n = 81) published in the Pediatric Infectious Disease Journal.
26 Nov 2015 Results (n=5989) comparing high dose safety and effectiveness with licensed doses published in the Advances in Therapy

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com